317 related articles for article (PubMed ID: 12086865)
1. Dissecting p53 tumor suppressor functions in vivo.
Schmitt CA; Fridman JS; Yang M; Baranov E; Hoffman RM; Lowe SW
Cancer Cell; 2002 Apr; 1(3):289-98. PubMed ID: 12086865
[TBL] [Abstract][Full Text] [Related]
2. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
3. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
4. Cell death regulation during multistep lymphomagenesis.
Hsu B; Marin MC; McDonnell TJ
Cancer Lett; 1995 Jul; 94(1):17-23. PubMed ID: 7621440
[TBL] [Abstract][Full Text] [Related]
5. Transgenic overexpression of a dominant negative mutant of FADD that, although counterselected during tumor progression, cooperates in L-myc-induced tumorigenesis.
Hueber AO; Bösser S; Zörnig M
Int J Cancer; 2004 Nov; 112(3):536-40. PubMed ID: 15382083
[TBL] [Abstract][Full Text] [Related]
6. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition.
Soengas MS; Alarcón RM; Yoshida H; Giaccia AJ; Hakem R; Mak TW; Lowe SW
Science; 1999 Apr; 284(5411):156-9. PubMed ID: 10102818
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
[TBL] [Abstract][Full Text] [Related]
8. p53 and p73 in suppression of Myc-driven lymphomagenesis.
Griesmann H; Schlereth K; Krause M; Samans B; Stiewe T
Int J Cancer; 2009 Jan; 124(2):502-6. PubMed ID: 18942718
[TBL] [Abstract][Full Text] [Related]
9. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation.
Raveh T; Droguett G; Horwitz MS; DePinho RA; Kimchi A
Nat Cell Biol; 2001 Jan; 3(1):1-7. PubMed ID: 11146619
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.
Valente LJ; Aubrey BJ; Herold MJ; Kelly GL; Happo L; Scott CL; Newbold A; Johnstone RW; Huang DC; Vassilev LT; Strasser A
Cell Rep; 2016 Mar; 14(8):1858-66. PubMed ID: 26904937
[TBL] [Abstract][Full Text] [Related]
11. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
12. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line.
Wang Y; Szekely L; Okan I; Klein G; Wiman KG
Oncogene; 1993 Dec; 8(12):3427-31. PubMed ID: 8247547
[TBL] [Abstract][Full Text] [Related]
13. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3.
Sharma K; Patel YC; Srikant CB
Mol Endocrinol; 1996 Dec; 10(12):1688-96. PubMed ID: 8961277
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice.
Kobzdej M; Matuszyk J; Strzadala L
Leuk Res; 2000 Jan; 24(1):33-8. PubMed ID: 10634643
[TBL] [Abstract][Full Text] [Related]
15. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
[TBL] [Abstract][Full Text] [Related]
16. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.
Burns TF; Bernhard EJ; El-Deiry WS
Oncogene; 2001 Aug; 20(34):4601-12. PubMed ID: 11498783
[TBL] [Abstract][Full Text] [Related]
17. p53 and p21waf-1 expression correlates with apoptosis or cell survival in poorly differentiated, but not well-differentiated, retinoblastomas.
Divan A; Lawry J; Dunsmore IR; Parsons MA; Royds JA
Cancer Res; 2001 Apr; 61(7):3157-63. PubMed ID: 11306502
[TBL] [Abstract][Full Text] [Related]
18. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent.
Trudel M; Lanoix J; Barisoni L; Blouin MJ; Desforges M; L'Italien C; D'Agati V
J Exp Med; 1997 Dec; 186(11):1873-84. PubMed ID: 9382886
[TBL] [Abstract][Full Text] [Related]
19. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase.
Shreeram S; Hee WK; Demidov ON; Kek C; Yamaguchi H; Fornace AJ; Anderson CW; Appella E; Bulavin DV
J Exp Med; 2006 Dec; 203(13):2793-9. PubMed ID: 17158963
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor.
Gurova KV; Kwek SS; Koman IE; Komarov AP; Kandel E; Nikiforov MA; Gudkov AV
Cancer Biol Ther; 2002; 1(1):39-44. PubMed ID: 12170763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
